Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with rheumatic diseases.
The article titled, "Antibody Response to SARS-CoV-2 mRNA Vaccines in Patients with Rheumatic Diseases in Japan: Interim Analysis of a Multicenter Cohort Study", is published in Modern Rheumatology.
According to the scientific article, antibody levels were “significantly lower” in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or Bucillamine or CNI (p<0.01).
READ: Revive Therapeutics updates further on its Phase 3 Bucillamine in coronavirus trial
The newly published study further validates the potential of Bucillamine in the treatment course for coronavirus (COVID-19), noted the company.
Bucillamine, an oral drug with anti-inflammatory and antiviral properties, is currently being evaluated in a Phase 3 clinical trial (NCT04504734) in patients with mild-to-moderate COVID-19.
The Toronto-based specialty life sciences company said it intends to seek US Food and Drug Administration (FDA) Emergency Use Authorization.
"The potential of Bucillamine for COVID-19 is evident with its anti-inflammatory and antiviral properties and its potential use in patients who have taken SARS-CoV-2 mRNA vaccines," Revive Therapeutics CEO Michael Frank in a statement.
Revive is focused on the research and development of therapeutics for infectious diseases and rare disorders.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive